• Skip to main content

ClinicalStudyConnect.com

Plain-Language Clinical Study and Ingredient Research

  • Heart & Blood Sugar
  • Bones & Joints
  • Everyday Vitamins
  • Reading Study Evidence
  • About

Does Testosterone Therapy Change Breast Tissue? New Research Explained

posted on November 18, 2026

If you saw a headline saying testosterone therapy changes breast tissue, here is the short version. A small study compared breast tissue from seven transgender men on testosterone cypionate injections with tissue from seven people who were not on it. It found lower activity in gene programs driven by estrogen and by progesterone receptors, mainly in hormone-receptor-positive cells. Blood estradiol was the same in both groups. The study measured gene activity, not cancer or any health outcome.

Who was studied

The piece you likely saw comes from Bioengineer.org testosterone breast tissue piece, a science-news site. It has no named author, and its footer credits Scienmag as the news source, so it is a rewrite of another outlet’s item. Its headline is “Testosterone Therapy Dampens Estrogen Signaling in Healthy Human Breast Tissue,” and it summarizes a peer-reviewed paper in the Journal of Mammary Gland Biology and Neoplasia (2026) by Phong, Song, Kim, Conrad and Gartner. The paper is titled “Single cell RNA-sequencing reveals that testosterone reduces estrogen signaling in the healthy human mammary gland.” You can find it through its journal paper on testosterone and estrogen signaling. The numbers below are the ones the Bioengineer.org piece reports.

The people in the main comparison were transgender men on testosterone cypionate injections, with blood testosterone at male-range levels. The comparison group was people not on testosterone, and the write-up frames them as cisgender women. All 14 donors in the main comparison had no breast cancer history. Their tissue came from gender-affirming chest contouring or cosmetic reduction mammoplasty.

Quick facts, as of 2026-11-18

These are the study details as the Bioengineer.org piece reports them, dated 2026-11-18.

Measure What the write-up reports
Study type Single-cell RNA sequencing of breast tissue removed in surgery, plus a check by immunofluorescence in a second group of donors
Main group 7 transgender men on intramuscular testosterone cypionate
Comparison group 7 people not on testosterone, matched for age, BMI and nulliparity
Blood testosterone 234 to 758 ng/dL in the testosterone group, versus 11 to 42 ng/dL in controls
Blood estradiol Did not differ significantly between groups
Cells analyzed 24,544 single cells in 12 clusters; hormone-receptor-positive luminal epithelial cells showed the most change
Genes turned down in those cells Amphiregulin; WNT4 (log2 fold change -3.31); RANKL/TNFSF11 (-4.47); PTHLH (-6.81, the most repressed)
Validation 19 donors (8 on testosterone, 11 controls): fewer progesterone-receptor-positive luminal cells in the testosterone group; estrogen receptor alpha protein showed a slight, non-significant upward trend
What was not measured Breast cancer, cancer risk, or any clinical outcome

What the study found, in plain terms

The main changes were in the cells that respond to hormones. In those cells, the piece says estrogen-driven and progesterone-receptor-driven gene programs were dampened. In plain terms, the cells showed less of that signaling. That is a change in tissue behavior, not a finding about cancer.

The second group of 19 donors was used to check one of those results. It showed fewer progesterone-receptor-positive luminal cells in the testosterone group. The write-up says the results matched an earlier tissue atlas by Raths and colleagues. That earlier work, described in a 2023 Cedars-Sinai androgen study, reported that breast cells in people on androgen therapy showed fewer signs of being influenced by estrogen. That 2023 study, a Cedars-Sinai press release distributed on Newswise, looked at nine transgender men and nine cisgender women.

What it means for you

The study shows that, in the cells it examined, testosterone was linked to lower gene activity. It does not show what that means for breast cancer or for your health. The main comparison had 14 donors, the check had 19, the tissue was sampled at a single point in time, and the authors say organoid and animal work is still needed.

If you want to judge studies like this yourself, our guide to understanding clinical study design explains why a snapshot of tissue is different from a trial that follows people over time.

Other studies on testosterone and breast tissue

Earlier studies look at different groups and different measures. They point in different directions, so it helps to see each one on its own terms.

  • A 2009 trial on mammogram density. Published in the Journal of Clinical Endocrinology and Metabolism, the 2009 mammographic density trial randomized 279 postmenopausal women not using estrogen-progestin therapy to placebo or a testosterone patch at 150 or 300 micrograms a day for 52 weeks. Of these, 250 had paired mammograms in the primary analysis, and the mean age was 54.6 years. Changes in percent dense tissue were small and not significantly different from placebo. The authors concluded the patch appears to have no significant effect on dense mammographic area in these women. This trial measured mammogram density, not gene activity, and it used a patch, not injections.
  • A 2008 review of testosterone and breast cancer. In 2008 review on testosterone and breast carcinoma, Shufelt and Braunstein wrote that “the preponderance of data suggests that T use in females is not associated with an increased risk of breast carcinoma.” They also reported that epidemiological analyses have shown mixed outcomes, with no clear consensus.
  • A 2018 case report. The 2018 case report from West Virginia University describes invasive ductal breast cancer in a 28-year-old transgender man receiving intramuscular testosterone. The authors say fewer than 20 cases of breast cancer in transgender men have been reported, and that more research is required.
  • A 2025 Swiss lab project. The 2025 Swiss cell research on testosterone, dated September 12, 2025, is funded by Swiss Cancer Research. It reports that breast cells grew particularly strongly when treated with estrogen, progesterone and testosterone together. The page says the research is still at an early stage.

Who this is about, and who it isn’t

The new study is about transgender men on testosterone cypionate injections at male-range levels, compared with people not on testosterone. Who a study enrolls changes what its results can tell you, as our guide to study populations dosing and outcomes explains. Cisgender men on testosterone replacement and women on low-dose testosterone are not groups this study covered.

Common mix-ups

  • “Reassurance” is the news site’s word. The Bioengineer.org piece closes by calling the findings “reassurance regarding the short-to-medium-term tissue dynamics.” That wording belongs to the site, not to a finding of the study.
  • A tissue change is not a cancer result. The study measured gene activity. It did not measure breast cancer, cancer risk or any clinical outcome, so it cannot tell you whether testosterone raises or lowers your risk.
  • Estrogen in the blood was the same. Blood estradiol did not differ significantly between the groups, which the piece uses to argue the tissue change is not just from lower circulating estradiol.
  • The low-dose suggestion is the site’s. The piece suggests the findings could inform low-dose androgen use in postmenopausal women and hormone-dependent breast cancer research. That suggestion goes beyond the people in this study.

Key dates

  • 2008: Shufelt and Braunstein review published in Menopause International.
  • 2009: 52-week mammogram density trial published in the Journal of Clinical Endocrinology and Metabolism.
  • 2018: Case report of breast cancer in a transgender man receiving testosterone.
  • March 8, 2023: Cedars-Sinai press release on the Cell Genomics androgen study.
  • September 12, 2025: Swiss Cancer Research project page on testosterone and breast cells.
  • 2026: Journal of Mammary Gland Biology and Neoplasia paper, volume 31(1), article 14.
  • November 18, 2026: Bioengineer.org piece published.

Questions to take to your doctor

A doctor is the person to ask about your own testosterone or hormone plan. These questions can help that conversation:

  • Does this study match my situation, including my hormone type, dose and body?
  • What breast screening makes sense for me, given my history?
  • Does this study change anything about my treatment plan?

By ClinicalStudyConnect.com Research Desk

Related reading

  1. Can Testosterone Affect Binge Eating? MSU Research Explained
  2. Does Estrogen Plus Testosterone Raise Bone Density? Study

Clinical Study Connect

Plain-Language Clinical Study and Ingredient Research

Topics

  • Research Guides
  • Ingredient Evidence
  • Study Design
  • Emerging Research
  • Safety

Publication

  • Editorial Standards
  • Research Methodology
  • Contact

Policies

  • Medical Disclaimer
  • Privacy Policy
© 2026 Clinical Study ConnectFor information only, not medical advice. See our Medical Disclaimer.